Biomimesys
Retrospective HCS Pharma 2022
We are glad starting a new Year! But nothing better than assessing what happened along the last one to glance back at the road traveled so far… and looking forward to what’s next!
We are glad starting a new Year! But nothing better than assessing what happened along the last one to glance back at the road traveled so far… and looking forward to what’s next!
End of last year, the american legislation has ratified that new drugs no longer need to be tested in animals to receive Food and Drug Administration (FDA) approval. This is a huge step toward animal-free validation of drugs, but it requires the design of a relevant and more predictive drug Read more…
BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…
Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into account flux-related aspects. BIOMIMESYS® being an ideal hydroscaffold™ for 3D cell culture, this webinar aims Read more…
We were glad to participate in FIE (Food Ingredients Europe) fair, which took place from the 6th to the 8th of December in Paris (as a new place for the fair France). Elodie attended it as a visitor, allowing us to meet again our usual partners and to meet future Read more…
Last week, our project leader Océane GUYOT was in Lisbon to participate in Skin Ageing & Challenges. We had the opportunity to present a short oral entitled Cell Imaging For Dermocosmetic Claims Substantation Through In Vitro Assessment On Cellular Skin Models. This presentation focused on the interest of cell imaging Read more…
Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into account flux-related aspects. BIOMIMESYS® being an ideal hydroscaffold™ for 3D cell culture, this webinar aims Read more…
BIOMIMESYS® permet de cultiver des cellules en 3D dans des conditions identiques à celle d’un organe humain et en utilisant exclusivement des composés physiologiques. Nous sommes non seulement capables de proposer un environnement dont la composition est celle du tissu désiré, mais qui en plus a les mêmes propriétés mécaniques de rigidité et de porosité.
The first edition of OncoLille Days congress took place from November 2th to 4th, 2022 in Lille. All 3 days were very rich in interesting presentations about interdisciplinary research in oncology, including biology, mathematics, human sciences, etc. Our project leader Véronique De Conto was pleased to present her poster about Read more…
We are pleased to participate to the 21st International Congress of the European Society of Toxicology In Vitro (ESTIV 2022), which will take place in Barcelona-Sitges, Spain, from 21st to 25th November 2022. Our project Leader in in vitro pharmacology Véronique De Conto will present her poster entitled “In vitro microenvironment modifies the neurotoxic Read more…
Nous avons eu le plaisir d’être invités par notre distributeur Dutscher, et en particulier par Romain Guegan, à présenter lors de la journée Necker-Imagine organisée à l’INEM (Institut Necker Enfants Malades) le 3 novembre dernier. Elodie a eu l’occasion de présenter aux chercheurs présents notre technologie BIOMIMESYS® pour une culture Read more…
Abstract: In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and Read more…
We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…
In October the expansion works started in HCS Pharma. The objective is to double the lab and office surface in the same building as our current premises, in the aim to expand BIOMIMESYS® production line to meet the growing demand while guaranteeing the quality of the products. These works will Read more…
Our project leader Méryl and our CBO Mathieu are currently attending CellME (Cell Manufacturing & Engineering) Forum taking place these days in Berlin, Germany. Méryl had the chance to present his work and the advantages of BIOMIMESYS® for organoid culture earlier today: Please feel free to discuss with them on Read more…
We are glad to announce the arrival of Gaspard in our team! Gaspard Delpouve obtained his Diploma of Advanced Technician in Biotechnologies in Lille in 2018, and in 2019 he passed a Bachelor’s degree in health biotechnologies at the University of Nantes. During his studies he completed several internships in Read more…
This is the end of the 6-month internship of Natacha in HCS Pharma, about the microenvironment modifications in Parkinson’s disease. Indeed, in vivo studies in the literature showed that the neuronal death in Parkinson’s disease involved Extracellular Matrix (ECM) modifications, including an increase in some components like collagen and a Read more…
Dear all, please feel free to contact Elodie who will be in RDV Carnot event in Paris (Espace Champerret, 17e arrondissement) tomorrow and on Thursday. Since HCS Pharma was selected as a laureate amongst innovative start-ups and SMEs for this ecent, she will be the first to pitch at 11:40 Read more…
About 90% of drug candidates fail in clinical trials, for efficacy- and toxicity-related reasons, which often involve the Central Nervous System (CNS). This high failure rate highlights a lack of relevance in experimental models used upstream, including human in vitro models. Indeed, they do not take into account the complexity Read more…
From different studies we know that more than 92% of drug candidates for Central Nervous System diseases fail in clinical trials, with 34% of safety failure. All that candidates have successfully passed in vitro steps and animal testing. Conclusion is straightforward : we have to deeply change biological models in Read more…
Our project director Elodie is participating to EUSAAT congress in Linz (Austria) this week, the European Congress on Alternatives to Animal Testing. She will have the pleasure to present our work aiming at bridging the gap between in vivo and in vitro situations by taking into account the extracellular matrix Read more…